Transferrin saturation and recovery from coma in cerebral malaria

Victor R. Gordeuk, Philip E Thuma, Christine E. McLaren, Godfrey Biemba, Stenford Zulu, Anton A. Poltera, Jim E. Askin, Gary M. Brittenham

Research output: Contribution to journalArticle

Abstract

To determine if the elevated transferrin saturations found in some patients with severe malaria are associated with an adverse outcome in cerebral malaria, we retrospectively measured baseline saturations in stored serum samples from 81 Zambian children with strictly defined cerebral malaria. The children had been treated with quinine, sulfadoxine- pyrimethamine, and intravenous infusions of either placebo (n = 39) or the iron chelator, desferrioxamine B (n = 42), in a previously reported trial (Gordeuk et al, N Engl J Med 327:1473, 1992). More than one-third of children in both the placebo- and iron chelator-treated groups had transferrin saturations exceeding 43%, which is 3 standard deviations above the expected mean for age. Among children receiving quinine and placebo, those with elevated transferrin saturations had a delayed estimated median time to recover full consciousness (68.2 hours) compared with those with saturations ≤43% (25.4 hours; P = .006). The addition of iron chelation to quinine therapy in children with high saturations appeared to hasten recovery (P = .046). We conclude that increased transferrin saturations may be associated with delayed recovery from coma during standard therapy for cerebral malaria and that serum iron and total iron binding capacity should be measured in future studies.

Original languageEnglish (US)
Pages (from-to)3297-3301
Number of pages5
JournalBlood
Volume85
Issue number11
StatePublished - Jun 1 1995
Externally publishedYes

Fingerprint

Cerebral Malaria
Transferrin
Coma
Iron
Quinine
Recovery
Placebos
Chelating Agents
Deferoxamine
Chelation
Serum
Consciousness
Intravenous Infusions
Malaria
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Medicine(all)
  • Hematology
  • Cell Biology

Cite this

Gordeuk, V. R., Thuma, P. E., McLaren, C. E., Biemba, G., Zulu, S., Poltera, A. A., ... Brittenham, G. M. (1995). Transferrin saturation and recovery from coma in cerebral malaria. Blood, 85(11), 3297-3301.

Transferrin saturation and recovery from coma in cerebral malaria. / Gordeuk, Victor R.; Thuma, Philip E; McLaren, Christine E.; Biemba, Godfrey; Zulu, Stenford; Poltera, Anton A.; Askin, Jim E.; Brittenham, Gary M.

In: Blood, Vol. 85, No. 11, 01.06.1995, p. 3297-3301.

Research output: Contribution to journalArticle

Gordeuk, VR, Thuma, PE, McLaren, CE, Biemba, G, Zulu, S, Poltera, AA, Askin, JE & Brittenham, GM 1995, 'Transferrin saturation and recovery from coma in cerebral malaria', Blood, vol. 85, no. 11, pp. 3297-3301.
Gordeuk VR, Thuma PE, McLaren CE, Biemba G, Zulu S, Poltera AA et al. Transferrin saturation and recovery from coma in cerebral malaria. Blood. 1995 Jun 1;85(11):3297-3301.
Gordeuk, Victor R. ; Thuma, Philip E ; McLaren, Christine E. ; Biemba, Godfrey ; Zulu, Stenford ; Poltera, Anton A. ; Askin, Jim E. ; Brittenham, Gary M. / Transferrin saturation and recovery from coma in cerebral malaria. In: Blood. 1995 ; Vol. 85, No. 11. pp. 3297-3301.
@article{b550ef0827d942b3ae3525cafb7e4205,
title = "Transferrin saturation and recovery from coma in cerebral malaria",
abstract = "To determine if the elevated transferrin saturations found in some patients with severe malaria are associated with an adverse outcome in cerebral malaria, we retrospectively measured baseline saturations in stored serum samples from 81 Zambian children with strictly defined cerebral malaria. The children had been treated with quinine, sulfadoxine- pyrimethamine, and intravenous infusions of either placebo (n = 39) or the iron chelator, desferrioxamine B (n = 42), in a previously reported trial (Gordeuk et al, N Engl J Med 327:1473, 1992). More than one-third of children in both the placebo- and iron chelator-treated groups had transferrin saturations exceeding 43{\%}, which is 3 standard deviations above the expected mean for age. Among children receiving quinine and placebo, those with elevated transferrin saturations had a delayed estimated median time to recover full consciousness (68.2 hours) compared with those with saturations ≤43{\%} (25.4 hours; P = .006). The addition of iron chelation to quinine therapy in children with high saturations appeared to hasten recovery (P = .046). We conclude that increased transferrin saturations may be associated with delayed recovery from coma during standard therapy for cerebral malaria and that serum iron and total iron binding capacity should be measured in future studies.",
author = "Gordeuk, {Victor R.} and Thuma, {Philip E} and McLaren, {Christine E.} and Godfrey Biemba and Stenford Zulu and Poltera, {Anton A.} and Askin, {Jim E.} and Brittenham, {Gary M.}",
year = "1995",
month = "6",
day = "1",
language = "English (US)",
volume = "85",
pages = "3297--3301",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Transferrin saturation and recovery from coma in cerebral malaria

AU - Gordeuk, Victor R.

AU - Thuma, Philip E

AU - McLaren, Christine E.

AU - Biemba, Godfrey

AU - Zulu, Stenford

AU - Poltera, Anton A.

AU - Askin, Jim E.

AU - Brittenham, Gary M.

PY - 1995/6/1

Y1 - 1995/6/1

N2 - To determine if the elevated transferrin saturations found in some patients with severe malaria are associated with an adverse outcome in cerebral malaria, we retrospectively measured baseline saturations in stored serum samples from 81 Zambian children with strictly defined cerebral malaria. The children had been treated with quinine, sulfadoxine- pyrimethamine, and intravenous infusions of either placebo (n = 39) or the iron chelator, desferrioxamine B (n = 42), in a previously reported trial (Gordeuk et al, N Engl J Med 327:1473, 1992). More than one-third of children in both the placebo- and iron chelator-treated groups had transferrin saturations exceeding 43%, which is 3 standard deviations above the expected mean for age. Among children receiving quinine and placebo, those with elevated transferrin saturations had a delayed estimated median time to recover full consciousness (68.2 hours) compared with those with saturations ≤43% (25.4 hours; P = .006). The addition of iron chelation to quinine therapy in children with high saturations appeared to hasten recovery (P = .046). We conclude that increased transferrin saturations may be associated with delayed recovery from coma during standard therapy for cerebral malaria and that serum iron and total iron binding capacity should be measured in future studies.

AB - To determine if the elevated transferrin saturations found in some patients with severe malaria are associated with an adverse outcome in cerebral malaria, we retrospectively measured baseline saturations in stored serum samples from 81 Zambian children with strictly defined cerebral malaria. The children had been treated with quinine, sulfadoxine- pyrimethamine, and intravenous infusions of either placebo (n = 39) or the iron chelator, desferrioxamine B (n = 42), in a previously reported trial (Gordeuk et al, N Engl J Med 327:1473, 1992). More than one-third of children in both the placebo- and iron chelator-treated groups had transferrin saturations exceeding 43%, which is 3 standard deviations above the expected mean for age. Among children receiving quinine and placebo, those with elevated transferrin saturations had a delayed estimated median time to recover full consciousness (68.2 hours) compared with those with saturations ≤43% (25.4 hours; P = .006). The addition of iron chelation to quinine therapy in children with high saturations appeared to hasten recovery (P = .046). We conclude that increased transferrin saturations may be associated with delayed recovery from coma during standard therapy for cerebral malaria and that serum iron and total iron binding capacity should be measured in future studies.

UR - http://www.scopus.com/inward/record.url?scp=0029036367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029036367&partnerID=8YFLogxK

M3 - Article

VL - 85

SP - 3297

EP - 3301

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -